# Study of a Human Bispecific Antibody VRC-HIVMAB0121-00-AB (CAP256J3LS) Administered Intravenously or Subcutaneously to Healthy Adults

> **NCT06585891** · PHASE1 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 24 (actual)

## Conditions studied

- HIV Infection

## Interventions

- **BIOLOGICAL:** VRC-HIVMAB0121-00-AB

## Key facts

- **NCT ID:** NCT06585891
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-10-07
- **Primary completion:** 2025-09-30
- **Final completion:** 2025-09-30
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2026-03-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06585891

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06585891, "Study of a Human Bispecific Antibody VRC-HIVMAB0121-00-AB (CAP256J3LS) Administered Intravenously or Subcutaneously to Healthy Adults". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06585891. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*